Usage of the new edaravone free radical scavenger (XAVRON) in the treatment of acute ischemic stroke

Usage of the new edaravone free radical scavenger (XAVRON) in the treatment of acute ischemic stroke

The purpose of the study is to evaluate the effectiveness of use of the drug edaravone for treatment of patients with acute cerebral infarction comparing to citicoline.

The results of the treatment of ischemic stroke by intravenous administration of edaravone (Xavron) and citicoline indicated a more pronounced elimination of neurological deficit in the group edaravone.

Learn more

Uncategorized

Astenic syndrome in a post-covid-19 patient (review and own experience)

Among the symptoms and syndromes that dominate the clinical picture of postcoid syndrome (POST-COVID-19), the signs of asthenia, increased fatigue, excessive exhaustion during normal daily activities, which form asthenic syndrome, are highlighted. For the treatment of postcoid asthenic syndrome, a combination of pathogenetically justified agents has been proposed: podaravone (Xavron), a mixture of L-arginine and...
Uncategorized

” Long-haulers “: patients with post-covid syndrome in routine clinical practice

At the beginning of the COVID 19 pandemic, SARS-CoV 2 disease was thought to be transient (like most respiratory viral infections). The World Health Organization later reported that the duration of a new coronavirus disease from the onset of the first symptoms to mild clinical recovery is ≈2 weeks, and in severe or moderate cases,...